In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Linaclotide | Synthetic analog Teduglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Gut and digestion | Gut and digestion | |
| Evidence | |||
| Amount of evidence | 389 | 362 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 57 (57 in people) | 73 (73 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 52 · 7 active8 more mention it but do not test it | 46 · 4 active4 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Linzess says: “IBS-C in adults and pediatric patients aged 7 years and older”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Linaclotide | Teduglutide |
|---|---|---|
| Adverse eventsWhole body | 2020 | 5050 |
| Gastrointestinal adverse eventsGastrointestinal |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Gattex says: “Adults and pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support”
3636
1717 |
| Gastrointestinal protectionGastrointestinal | 362187 | 47641 |
|---|
| PharmacokineticsPharmacology | 7241 | 17134 |
|---|
| Quality of lifeGastrointestinal | 33 | 1313 |
|---|
| Receptor activity and mechanismNervous system and cognition | 3061014 | 1212 |
|---|
| Gastrointestinal motilityGastrointestinal | 33 | 66 |
|---|
| Heart functionCardiovascular | 11 | 33 |
|---|
| Inflammation markersKidney and urinary | 321 | 918 |
|---|
| MortalityWhole body | 11 | 22 |
|---|
| Tumor growthGastrointestinal | 44 | 11 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 52 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ironwood Pharmaceuticals, Inc.1,743 participantsSept 2008 to Mar 2012
Irritable Bowel Syndrome With Constipation · Chronic Constipation
AstraZeneca1,722 participantsJul 2013 to May 2015
Irritable Bowel Syndrome With Constipation (IBS-C)
Forest Laboratories1,559 participants31 Oct 2008 to 31 Jan 2012
Chronic Constipation · Irritable Bowel Syndrome With Constipation
8 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 46 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Shire88 participants21 Sept 2009 to 24 Jan 2013
Short Bowel Syndrome
Shire86 participants25 Nov 2008 to 25 Jan 2011
Short Bowel Syndrome
Shire84 participants25 May 2004 to 6 Jul 2007
Short Bowel Syndrome
4 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Linaclotide | Teduglutide |
|---|---|---|
| Gastrointestinal protectionGastrointestinalCompared as: value in the arm that got the peptide, in % | 15.7% Primary response · linaclotide 145 μg Placebo: 7.6% Dose studied: 145 μg once daily12 weeksn not reported2015 | No comparable result 5 randomized-trial results measure it in another way or another unit. |
| Receptor activity and mechanismGastrointestinalCompared as: value in the arm that got the peptide, in milliseconds | 19 milliseconds P1 latency change from baseline Placebo: 3 milliseconds Dose studied: 290 µg10 weeksn = 392020 | No randomized trial result 12 results from other study designs. |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 9.4% Diarrhea Placebo: 1.2% Dose studied: 290 μg once dailyn = 8392018 | No comparable result 1 randomized-trial result measure it in another way or another unit. |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 5.7% Discontinuation due to diarrhea · linaclotide 290 µg Placebo: 1.3% Dose studied: 290 µg once daily8 weeksn = 1672020 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
15.7%
Primary response · linaclotide 145 μg
Placebo: 7.6%
Dose studied: 145 μg once daily12 weeksn not reported2015
No comparable result
5 randomized-trial results measure it in another way or another unit.
19 milliseconds
P1 latency change from baseline
Placebo: 3 milliseconds
Dose studied: 290 µg10 weeksn = 392020
No randomized trial result
12 results from other study designs.
9.4%
Diarrhea
Placebo: 1.2%
Dose studied: 290 μg once dailyn = 8392018
No comparable result
1 randomized-trial result measure it in another way or another unit.
5.7%
Discontinuation due to diarrhea · linaclotide 290 µg
Placebo: 1.3%
Dose studied: 290 µg once daily8 weeksn = 1672020
No comparable result
2 randomized-trial results measure it in another way or another unit.